NCT04941274View on ClinicalTrials.gov

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

March 1, 2028

Study Completion Date

June 1, 2028

Conditions
Kaposi Sarcoma
Interventions
DRUG

Abemaciclib

An initial dose of 200 mg twice daily and at an MTD dose will be administered orally every day of each 28-day cycle.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH